Shares of CARSGEN-B (HKEX: 02171) rose more than 7% during the trading session. At the time of writing, the stock is up 5.32% to HK$16.83, with a trading turnover of HK$52.48 million.

On July 16th, CARSGEN announced that, according to a notice from the National Healthcare Security Administration, its product Kailimei® (SuRuiji Orelencel Injection, product code: CT041, a Claudin18.2-targeted autologous CAR-T cell therapy candidate) has successfully passed the preliminary formal review for the 2026 National Commercial Health Insurance Innovation Drug Catalog adjustment. As the world's first approved CAR-T therapy for solid tumors, this product marks a historic leap in cellular immunotherapy from hematological malignancies to solid tumors, precisely addressing a critical clinical gap in the treatment of advanced gastric cancer.